Edoxaban

Edoxaban
Clinical data
Trade names	Savaysa, Lixiana, Roteas, others
Other names	DU-176b
AHFS/Drugs.com	Monograph
MedlinePlus	a614055
License data	US DailyMed: Edoxaban;
Routes of; administration	By mouth
ATC code	B01AF03 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	62%; Tmax 1–2 hours
Protein binding	55%
Metabolism	minimal CES1, CYP3A4/5, hydrolysis, glucuronidation
Elimination half-life	10–14 hours
Excretion	62% feces, 35% urine
Identifiers
	IUPAC name N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;
CAS Number	480449-70-5 ;
PubChem CID	10280735;
IUPHAR/BPS	7575;
DrugBank	DB09075 ;
ChemSpider	8456212 ;
UNII	NDU3J18APO;
KEGG	D09710 ;
ChEBI	CHEBI:85973 ;
CompTox Dashboard (EPA)	DTXSID50197398 ;
Chemical and physical data
Formula	C24H30ClN7O4S
Molar mass	548.06 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C;
	InChI InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1 ; Key:HGVDHZBSSITLCT-JLJPHGGASA-N ;
	(what is this?) (verify)

Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor.^[3] It is taken by mouth.^[3]

Compared with warfarin it has fewer drug interactions.^[6]

It was developed by Daiichi Sankyo and approved in July 2011, in Japan for prevention of venous thromboembolisms following lower-limb orthopedic surgery.^[7] It was also approved in the United States by the Food and Drug Administration (FDA) in January 2015, for the prevention of stroke and non–central-nervous-system systemic embolism.^[8]^[9] It was approved for use in the European Union in June 2015.^[4] It is on the World Health Organization's List of Essential Medicines.^[10]

^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ ^a ^b ^c "Savaysa- edoxaban tosylate tablet, film coated". DailyMed. 24 April 2020. Retrieved 23 July 2020.
^ ^a ^b Cite error: The named reference Lixiana EPAR was invoked but never defined (see the help page).
^ "Roteas EPAR". European Medicines Agency (EMA). 4 May 2017. Retrieved 25 September 2020.
^ ^a ^b ^c ^d ^e Parasrampuria DA, Truitt KE (June 2016). "Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting FactorXa". Clinical Pharmacokinetics. 55 (6): 641–55. doi:10.1007/s40262-015-0342-7. PMC 4875962. PMID 26620048.
^ "First market approval in Japan for Lixiana (Edoxaban)". Daiichi Sankyo Europe GmbH (Press release). 22 April 2011. Archived from the original on 6 November 2013.
^ O'Riordan M (9 January 2015). "FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention". Medscape. Retrieved 10 January 2015.
^ "Drug Approval Package: Savaysa (edoxaban tosylate) Tablets NDA #206316". U.S. Food and Drug Administration (FDA). 13 February 2015. Retrieved 23 July 2020.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.